Early and late administration of MnTE-2-PyP5+ in mitigation and treatment of radiation-induced lung damage
Benjamin Gauter-Fleckenstein(Heidelberg University), Željko Vujašković(Harvard University), Júlio S. Rebouças(Duke Medical Center), Kouros Owzar(Duke University), Katharina Fleckenstein(Heidelberg University), Ines Batinic̈‐Haberle(Duke University), Jiang Chen(Duke University)
Cited by 108
Related Papers
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
|Journal of Clinical Oncology|2008|655
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
|Journal of Clinical Oncology|2009|507